ACRIVON THERAPEUTICS INC. - COMMON STOCK

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

08 Jan 2026 07:30:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

06 Jan 2026 07:30:00 By Nasdaq GlobeNewswire

UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

17 Dec 2025 09:34:04 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates

17 Dec 2025 07:30:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

13 Nov 2025 16:10:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference

22 Oct 2025 16:15:41 By Nasdaq GlobeNewswire

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 Oct 2025 16:30:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

13 Aug 2025 16:15:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

14 May 2025 16:10:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

25 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

07 Apr 2025 16:05:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

27 Mar 2025 17:44:36 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

19 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer

05 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

13 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium

17 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

16 Oct 2024 16:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

11 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

14 Sep 2024 03:10:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference

10 Sep 2024 08:00:00 By Nasdaq GlobeNewswire